July 27, 2021

Neuro42 MRI 400x275Neuro42, which develops diagnostic imaging and image-guided surgical interventions of the brain, has announced raising $6.5 million in a Series A funding round. The financing will be used to advance the development of its MRI and robot platform, allowing physicians to diagnose brain injuries in acute settings, and treat neurological diseases intraoperatively under live imaging.

The funding round was led by Zepp Health, and was joined by ShangBay Capital and angel investors Krishna R. Bhupal and Philip Dolan. To date, neuro42 has raised $7.8 million, of which $1.3 million was in an oversubscribed seed round that closed earlier this year.

“The investment will fast-track our progress in bringing our products to the masses and creating a meaningful impact for neuro-physicians and neurosurgeons in treating their patients,” said Dr. Amit Vohra, founder and CEO of neuro42.

The company was formed to focus on brain imaging and treatment of various brain conditions including, but not limited to, stroke, hydrocephalus, epilepsy and various brain tumors. The company is developing and commercializing an intraoperative MR, AI and robot that allows easy access to MR imaging for screening, diagnosis, and intervention.

“Neuro42 and their team of medical and scientific experts encompass deep industry knowledge, triggering the next wave of growth in the field of neuroimaging and interventions,” said Mike Yeung, chief operating officer at Zepp Health. “The company offers a unique and scalable opportunity, combining proprietary MRI technology with artificial intelligence and robotics.”

Neuro42 said one of the most significant advantages of its technology is that the novel scanner allows for robotic procedures outside of the traditional magnetic resonance suite, expanding the possibilities of intraoperative image guidance and disease treatment.

More details on the company can be found at the neuro42 website.